2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2491 Real-world single-center evaluation of EBMT provisional criteria of ruxolitinib failure in steroid-refractory chronic graft-versus-host disease: Ruxolitinib failure pattern and current clinical management of ruxolitinib failure

Sergio Rodriguez-Rodriguez, MD, MSc, Eshrak Al-Shaibani, MD2, Tommy Alfaro Moya, MD3, Igor Novitzky-Basso, MD,PhD4, Ivan Pasic, BSc5, Auro Viswabandya, MBBS MD DM6, Fotios Michelis, MD, PhD7, Rajat Kumar, FRCPC8, Jonas Mattsson, MD PhD9, Dennis Dong Hwan Kim, MD/PhD10
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada

Background: Ruxolitinib (RUX) is now accepted as a second-line therapy for steroid-refractory/dependent chronic graft-versus-host disease (SR-cGvHD), with debate about how to define and manage RUX failure. Recently, the EBMT expert panel presented provisional criteria for RUX failure at the EBMT 2026 meeting 1) progression at day 28, 2) mixed response from month 1, 3) inadequate response between months 1-3, 4) no response by month 3, and 5) progression or new organ GvHD involvement after month 3; however, these criteria have never been systematically evaluated for their feasibility. The present study evaluated the pattern and timing of RUX failure, and pretreatment predictors of early response, in patients with SR-cGvHD.

Methods: A total of 79 adults were included who had been treated with RUX for SR-cGvHD between January 2016 and January 2025. RUX failure was determined based on the EBMT provisional criteria and grouped as lack of efficacy, toxicity/intolerance, or non-relapse mortality (NRM). Management for RUX failure and the next-line systemic agent after RUX were captured. Overall response rate (ORR) was defined as complete or partial response per NIH criteria; mixed response was defined as progression or non-response in one organ with a partial/complete response in others. Outcomes were assessed at day 28, month 2, month 3, and every 3 months thereafter. Covariates at RUX initiation (cGvHD severity, subtype, organ involvement, prior acute GvHD, and performance status) were tested as predictors of ORR and of failure mode.

Results: Median age was 52 years (IQR 36-64), Median time from HCT to cGvHD was 5.7 months (IQR 4.6-8.0), and 46 patients (58%) had overlap syndrome. The median time interval from cGvHD diagnosis to RUX therapy was 10.3 months (IQR 3.9-34.3); at RUX initiation, cGvHD grade was severe in 29 (37%), with a median of 3 organs involved (IQR 2-4).

RUX failure occurred in 48 of 79 patients (61%), typically driven by lack of efficacy. Most (n=30; 62%) met one of the five EBMT criteria: 1) progression at day 28 (n=2; 4%), 2) mixed response from month 1 (n=1; 2%), 3) inadequate response between months 1-3 (n=4; 8%), 4) no response by month 3 (n=1; 2%), 5) progression or new organ involvement after month 3 (n=22; 46%). The remaining 18 (38%) failed due to flare during tapering (n=4; 8%), toxicity/intolerance (n=10; 21%), and NRM (n=4; 8%). Median time to RUX failure was 10.4 months (95% CI 6.4-not reached). The overall cumulative incidence of RUX failure was 51.9% at 1 year and 58.8% at 3 years. When stratified by failure mode, cumulative incidence of failure by month 3 plateaued at 10.1%, whereas progression after month 3 reached 26.6% at 1 year, and toxicity/intolerance 11.4%.

Among 34 patients who failed due to lack of efficacy to RUX, 31 (91%) started an alternative agent, usually added while RUX was continued, including two patients who progressed at day 28, one with a mixed response from month 1, three of four patients with inadequate response between months 1 and 3, one without response by month 3, 20 of 22 who progressed after month 3, and all four flaring during tapering. Overall, 20 (59%) patients received add-on therapy while keeping RUX, nine (26%) an add-on with RUX taper, and two (6%) switched therapy. The next agent was captured in 29 patients: belumosudil (n=11;38%), extracorporeal photopheresis (n=9; 31%), axatilimab (n=2; 7%), and other agents in seven (24%). Toxicity/intolerance was managed with RUX taper in 8 of 10; RUX was discontinued in seven patients, four due to NRM.

Responses to RUX deepened over time. ORR rose from 43% (n=34/79) at day 28 to 65% (n=49/75) at month 3. Among day-28 non-responders, 13 of 45 (29%) had a mixed response, as did 12 of 36 (33%) at month 2. Baseline cGvHD severity was the only predictor for ORR at day 28 (severe vs. moderate: OR 0.35, 95% CI 0.13-0.94, p=0.038) and at month 3 (OR 0.36, 95% CI 0.13-0.98, p=0.045), attenuated in the multivariable analysis (day 28 OR 0.37, p=0.070; month 3 OR 0.33, p=0.061). No covariates differed across the failure-mode groups (all p≥0.280).

Conclusion: Real-world definitions and management of RUX failure mirrored the emerging consensus; however, most RUX failure occurred beyond 3 months, whereas toxicity-driven failure occurred early, indicating that surveillance should extend beyond month 3. Among lack-of-efficacy failures, next agents were predominantly used as add-ons with RUX overlap. Prospective validation is warranted.

Sergio Rodriguez-Rodriguez, MD, MSc: No relevant conflicts of interest to declare.